Literature DB >> 4125851

Serum thyroxine levels in patients receiving L-thyroxine suppression or replacement therapy.

A Kahn.   

Abstract

Serum thyroxine (T(4)) and protein-bound iodine (PBI) levels were measured in 140 adult patients receiving L-thyroxine, 0.2 or 0.3 mg. daily for at least six months, as suppression or replacement therapy. All were judged to be clinically euthyroid at the time of the measurements. The mean PBI was 8.3 mug./100 ml. and the mean T(4) was 10.8 mug./100 ml. The range of values for the PBI was 3.5 to 13.2 and for the T(4) was 3.1 to 17.0. Because of the wide range of values, it is considered that the judgement of whether a patient is euthyroid on L-thyroxine therapy should be based primarily on clinical evaluation and only secondarily on serum T(4) or PBI levels.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4125851      PMCID: PMC1946842     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  10 in total

1.  ANOMALOUS EFFECTS OF CERTAIN PREPARATIONS OF DESICCATED THYROID ON SERUM PROTEIN-BOUND IODINE.

Authors:  L E BRAVERMAN; S H INGBAR
Journal:  N Engl J Med       Date:  1964-02-27       Impact factor: 91.245

2.  DETERMINATION OF THYROXINE UTILIZING THE PROPERTY OF PROTEIN-BINDING.

Authors:  B E MURPHY; C J PATTEE
Journal:  J Clin Endocrinol Metab       Date:  1964-02       Impact factor: 5.958

3.  BINDING OF THYROXINE BY SERUM PROTEINS EVALUATED BY EQUILIBRUM DIALYSIS AND ELECTROPHORETIC TECHNIQUES. ALTERATIONS IN NONTHYROIDAL ILLNESS.

Authors:  J H OPPENHEIMER; R SQUEF; M I SURKS; H HAUER
Journal:  J Clin Invest       Date:  1963-11       Impact factor: 14.808

4.  Clinically inactive thyroid U.S.P. A preliminary report.

Authors:  B CATZ; E GINSBURG; S SALENGER
Journal:  N Engl J Med       Date:  1962-01-18       Impact factor: 91.245

5.  Suppression of thyrotropin (h-TSH) in serums of patients with myxedema of varying etiology treated with thyroid hormones.

Authors:  G E Cotton; C A Gorman; W E Mayberry
Journal:  N Engl J Med       Date:  1971-09-02       Impact factor: 91.245

6.  The extrathyroidal conversion rate of thyroxine to triiodothyronine in normal man.

Authors:  C S Pittman; J B Chambers; V H Read
Journal:  J Clin Invest       Date:  1971-06       Impact factor: 14.808

7.  Clinical evaluation of a new method for the determination of serum thyroxine.

Authors:  B E Murphy; C J Pattee; A Gold
Journal:  J Clin Endocrinol Metab       Date:  1966-03       Impact factor: 5.958

8.  Evaluation of adjusted total thyroxine (free thyroxine index) as a measure of thyroid function.

Authors:  R B Stein; L Price
Journal:  J Clin Endocrinol Metab       Date:  1972-01       Impact factor: 5.958

9.  Conversion of thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects.

Authors:  L E Braverman; S H Ingbar; K Sterling
Journal:  J Clin Invest       Date:  1970-05       Impact factor: 14.808

10.  The effects of an acute load of thyroxine on the transport and peripheral metabolism of triiodothyronine in man.

Authors:  K A Woeber; E Hecker; S H Ingbar
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

  10 in total
  4 in total

Review 1.  Euthyroid hyperthyroxinemia.

Authors:  R Rajatanavin; L E Braverman
Journal:  J Endocrinol Invest       Date:  1983-12       Impact factor: 4.256

2.  What is the best test for monitoring levothyroxine therapy?

Authors:  M M Wong; R Volpé
Journal:  Can Med Assoc J       Date:  1981-05-01       Impact factor: 8.262

3.  Elevated serum thyroxine concentration in patients receiving "replacement" doses of levothyroxine.

Authors:  J C Ingbar; M Borges; S Iflah; R E Kleinmann; L E Braverman; S H Ingbar
Journal:  J Endocrinol Invest       Date:  1982 Mar-Apr       Impact factor: 4.256

4.  Thyroxine uptake by human hepatoma cells from serum of patients submitted to long-term thyroxine suppressive therapy.

Authors:  L Bartalena; E Martino; M Falcone; A Pacchiarotti; A Pinchera
Journal:  J Endocrinol Invest       Date:  1988-10       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.